Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04571840 · ClinicalTrials.gov registry record · NA

Prostate Imaging Using MRI +/- Contrast Enhancement

A NA study of Prostate Cancer, sponsored by University College, London.

Active
Registry status
NA
Development phase
500
Enrollment target
20
Study locations

NCT04571840: Active NA study of Prostate Cancer, sponsored by University College, London.

NCT04571840 is a NA study of Prostate Cancer that is active but no longer recruiting, run by University College, London. The registered enrollment target is 500 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (18% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04571840, a NA study of Prostate Cancer, is active but no longer recruiting, sponsored by University College, London.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
500 participants
Enrollment target
20
Study locations

Study Summary

This prospective clinical trial (PRostate Imaging using Mri +/- contrast Enhancement (PRIME)) aims to assess whether biparametric MRI (bpMRI) is non-inferior to multiparametric mpMRI (mpMRI) in the detection of clinically significant prostate cancer. This means that we are comparing MRI scans that requires injection of IV contrast (the current standard practice) versus MRI scans that can be performed without IV contrast in the detection of prostate cancer.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST Multiparametric MRI +/- prostate biopsy
  • DIAGNOSTIC_TEST Biparametric MRI +/- prostate biopsy

Study Locations (20)

Other

  • Centro de Urologia - Buenos Aires
  • Monash University - Melbourne
  • Peter MacCallum Cancer Centre - Melbourne E.
  • Ghent University Hospital - Ghent
  • Hospital Sírio-Libanês - São Paulo
  • Princess Margaret Cancer Centre - Toronto
  • Herlev and Gentofte Hospital - Copenhagen
  • Helsinki University Hospital - Helsinki
  • Bordeaux Pellegrin University Hospital - Bordeaux
  • CHU Lille - Lille
  • Sorbonne Université - Paris
  • Heinrich Heine University Düsseldorf - Düsseldorf
  • Essen University Hospital - Essen
  • University Hospital Frankfurt - Frankfurt
  • Martini Klinik - Hamburg
  • San Raffaele Hospital - Milan

New York

  • NYU Langone - New York
  • Icahn School of Medicine (Mount Sinai) - New York
  • New York Presbyterian Hospital - New York

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2022-03-22
Est. Completion 2025-03-01
Phase NA
University College, London

8 total trials

What the registry record for NCT04571840 still lists

NCT04571840 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (18% lower).

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Multiparametric MRI +/- prostate biopsy is the first listed.

NCT04571840 names 20 study sites across 3 states, led by Other, New York, Minnesota.

Frequently Asked Questions

What is clinical trial NCT04571840 about?

NCT04571840 is a clinical study titled "Prostate Imaging Using MRI +/- Contrast Enhancement". This prospective clinical trial (PRostate Imaging using Mri +/- contrast Enhancement (PRIME)) aims to assess whether biparametric MRI (bpMRI) is non-inferior to multiparametric mpMRI (mpMRI) in the detection of clinically significant prostate cancer. This means that we are comparing MRI scans that ...

What is the current status of trial NCT04571840?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2022-03-22. Estimated completion is 2025-03-01.

What conditions does trial NCT04571840 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT04571840?

The interventions under investigation include: Multiparametric MRI +/- prostate biopsy (DIAGNOSTIC_TEST), Biparametric MRI +/- prostate biopsy (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT04571840?

This trial is sponsored by University College, London, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04571840 being conducted?

This trial has 20 study locations across Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04571840's enrollment target sits among peer trials

500 105th of 735 higher than 623 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04571840, the US trial registry maintained by the National Library of Medicine. NCT04571840 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.